Overview
IRWD market data
Price History
IRWD price chart
Valuation & Profitability
- P/E (TTM)
- 6.87 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.15 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.21 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 28.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.84 – $5.78 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $701.4M · P/B 2.91 · P/S 1.94.
Company News
8-K filing — IRONWOOD PHARMACEUTICALS INC (IRWD)SEC EDGAR · Aug 6, 2026, 11:12 AM
Ironwood Pharmaceuticals Raises FY2026 Sales Guidance from $450.000M-$475.000M to $460.000M-$485.000M vs $460.118M EstBenzinga · Aug 6, 2026, 11:09 AM
Ironwood Pharmaceuticals Q2 Adj. EPS $0.31 Misses $0.36 Estimate, Sales $113.041M Miss $114.844M EstimateBenzinga · Aug 6, 2026, 11:09 AM
Ironwood Pharma Initiates Phase 3 STARS‑2 Trial Of Apraglutide In Short Bowel Syndrome With Intestinal FailureBenzinga · Jul 14, 2026, 11:32 AM
Ironwood Pharma Says FDA Approves Use Of LINZESS In Pediatric Patients 2 Years Of Age And Older With Functional ConstipationBenzinga · May 27, 2026, 2:10 PM